The Immunological Effect of Photopheresis in Children with Newly Diagnosed Type 1 Diabetes

Faresjö, Maria; Ernerudh, Jan; Berlin, Gösta; García, J. Luz Tovar; Ludvigsson, Johnny

doi:10.1203/01.pdr.0000176906.42001.c3

Cited by 15 publications

(12 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings probably reflect an activation of lymphocytes as part of the natural course of T1D and that ECP may have some suppressant effects, preventing lymphocyte activation . ECP produced cytokine changes reflecting a Th2‐like response . Placebo‐treated patients showed reduced T‐cell‐associated activity, which seemed to be counteracted by ECP, whereas ECP‐treated patients showed preserved T‐cell activity.…”

Section: Mode Of Actionmentioning

confidence: 96%

Guidelines on the use of extracorporeal photopheresis

Knobler

Berlin

Calzavara‐Pinton

et al. 2013

Acad Dermatol Venereol

189

206

View full text Add to dashboard Cite

BackgroundAfter the first investigational study on the use of extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma was published in 1983 with its subsequent recognition by the FDA for its refractory forms, the technology has shown significant promise in the treatment of other severe and refractory conditions in a multi-disciplinary setting. Among the major studied conditions are graft versus host disease after allogeneic bone marrow transplantation, systemic sclerosis, solid organ transplant rejection and inflammatory bowel disease.Materials and methodsIn order to provide recognized expert practical guidelines for the use of this technology for all indications the European Dermatology Forum (EDF) proceeded to address these questions in the hands of the recognized experts within and outside the field of dermatology. This was done using the recognized and approved guidelines of EDF for this task.Results and conclusionThese guidelines provide at present the most comprehensive available expert recommendations for the use of extracorporeal photopheresis based on the available published literature and expert consensus opinion.

show abstract

Section: Mode Of Actionmentioning

confidence: 96%

Guidelines on the use of extracorporeal photopheresis

Knobler

Berlin

Calzavara‐Pinton

et al. 2013

Acad Dermatol Venereol

189

206

View full text Add to dashboard Cite

show abstract

“…77 Studies with ECP have also been conducted in a number of other diseases, including pemphigus vulgaris 78 and type 1 diabetes. 79 …”

Section: Ecp In Other Diseasesmentioning

confidence: 99%

Extracorporeal photopheresis: Past, present, and future

Knobler

Barr

Couriel

et al. 2009

Journal of the American Academy of Dermatology

113

View full text Add to dashboard Cite

“…In GvHD and in type 1 diabetes, an ECP‐mediated shift toward Th2 has been reported (46, 47). One potential mechanism that might underlie this observation is that ECP‐treated dendritic cells can be primed to increase Th2‐producing T cells (47, 48).…”

Section: Discussionmentioning

confidence: 99%

Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndrome

McGirt¹,

Thoburn

Hess

et al. 2010

Photodermatology, Photoimmunology &Amp; Photomedicine

View full text Add to dashboard Cite

Summary Background Extracorporeal photopheresis (ECP) has been utilized for more than 20 years to treat cutaneous T-cell lymphoma (CTCL), but a clinical response can take up to 9 months to manifest. This study was undertaken to determine whether clinical features, laboratory values, cytokine levels, or gene expression levels of tumor markers are useful to predict the subsequent response to ECP in CTCL patients with blood involvement. Methods Twenty-one patients with CTCL treated with ECP as monotherapy for at least 6 months were retrospectively identified. Laboratory and clinical data and blood obtained at baseline, 3, and 6 months of treatment were used for analysis. Results In pretreatment blood specimens, a lower percentage of Sézary cells and a higher absolute eosinophil count were associated with a favorable clinical response. Clinical evidence of an early response after 3 months of ECP did not reliably predict a favorable response at 6 months or beyond. Comparison of cytokines, gene transcripts, and other laboratory measures of disease did not correlate with the subsequent clinical response, although lactate dehydrogenase levels tended to decrease progressively in ECP-responsive cases and increase progressively in ECP-non-responsive cases. Additionally, serum levels of TNF-α significantly increased from baseline to 6 months of ECP, but was not found to correlate with the clinical response. Conclusions Although we found that increased eosinophils and decreased percentage of Sézary cells were associated with a favorable clinical response to ECP, we were not able to identify the predictors of ECP response within the first 3 months of treatment.

show abstract

The Immunological Effect of Photopheresis in Children with Newly Diagnosed Type 1 Diabetes

Cited by 15 publications

References 47 publications

Guidelines on the use of extracorporeal photopheresis

Guidelines on the use of extracorporeal photopheresis

Extracorporeal photopheresis: Past, present, and future

Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndrome

Contact Info

Product

Resources

About